https://www.lifematrixtechnologies.com/  

8092 Zürich, c/o Wyss Zurich, Weinberstrasse 35

Based in Zurich, Switzerland, LifeMatrix Technologies AG, is a pre-revenue, high-tech startup company spun out of the Institute for Regenerative Medicine at the University of Zurich. Our team combines world leading science in cardiovascular tissue engineering with in-depth entrepreneurial expertise in medical biomimetic device development. The award winning LifeMatrix technology platform is backed by >20 years of research with >150 peer-reviewed publications and a strong patent portfolio. LifeMatrix is currently supported by the Wyss Zurich, a joint accelerator of the University of Zurich and ETH Zurich.

http://www.lmtbio.com  

8952 Schlieren, Grabenstrasse 3

 +41 44 733 85 85
 info@lmtbio.com

LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. It was founded as a spin-off of GlycoVaxyn AG, which was acquired by GSK in February 2015 following a two-year collaboration. LimmaTech is developing vaccines exclusively for GSK and actively explores applications of glycoengineering and protein glycosylation technology in other fields.